Eli Lilly and AbCellera Collaboration Result LY-C0V555
A lot of discoveries, followed by thorough experimentation beyond the vaccines, are taking place in the biotechnology and large biopharmaceutical companies to defeat COVID-19. The most recently discovered product by AbCellera, which was developed by Eli Lilly (LLY), is LY-CoV555 - a potent, neutralizing IgG1 monoclonal antibody (mAb), directed . . .
This content is for paid subscribers.
Impacting News
September 16, 2020